Summary: A better understanding of the mechanisms by which tumor rejection succeeds and fails is needed to improve immunotherapies. Here, Anagnostou and colleagues find that mutations predicted to be the most immunogenic are preferentially lost when cancer progresses through checkpoint blockade. Cancer Discov; 7(3); 250–1. ©2017 AACR.
See related article by Anagnostou et al., p. 264.
- ©2017 American Association for Cancer Research.